[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital Ostrava\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":657},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,47,77,101,127,154,183,207,233,263,291,320,343,367,391,416,435,459,483,507,530,557,579,608,634],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100634017","the-effect-of-eeg-and-bis-guided-anaesthesia-on-the-incidence-of-emergent-delirium-in-children-100634017",false,"NCT07534215","The Effect of EEG and BIS-guided Anaesthesia on the Incidence of Emergent Delirium in Children","Comparison of the Effect of EEG and BIS-guided Anaesthesia on the Incidence of Emergent Delirium in Children: a Prospective Monocentric Study","Inclusion Criteria:\n\n* Patient aged 1-6 years indicated for surgery (hernioplasty, orchidopexy)\n* Consent of parents\u002Flegal guardians\n* Health status corresponding to ASA (American Society of Anesthesiologists) I and II\n\nExclusion Criteria:\n\n* Disagreement of parents\u002Flegal guardians with inclusion in the study\n* Neurological disease, severe hearing and vision impairment\n* Health status corresponding to ASA (American Society of Anesthesiologists) III and above","ALL","1 Year","6 Years",{"count":21,"type":22},540,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of the study is to compare two modalities of measuring the depth of general anaesthesia on the incidence of emergent delirium in children.",[28],"Emergence Delirium, Anesthesia",[30,31,32,33],"Emergence Delirium","EEG","Bispectral Index","General anaesthesia","RECRUITING","2026-04-16",{"date":37,"type":38},"2026-04-21","ACTUAL",{"date":40,"type":38},"2026-01-01",{"date":42,"type":22},"2028-12",{"name":44,"class":45},"University Hospital Ostrava","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100631312","phase-2-safety-and-efficacy-of-low-dose-anticoagulation-with-argatroban-and-enoxaparin-on-ecmo-100631312","NCT07499037","Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO","Low-dose Versus Standard-dose Anticoagulation With Argatroban and Enoxaparin During Extracorporeal Membrane Oxygenation Controlled by Anti-IIa and An-ti-Xa, Respectively","Inclusion Criteria:\n\n* ECMO support with anticoagulation using argatroban\u002Fenoxaparin\n* Age ≥ 18 years\n* Obtaining informed consent in accordance with the procedure specified in the protocol\n\nExclusion Criteria:\n\n* Enrolment in the lung transplant program at Motol University Hospital\n* Known hypersensitivity to the components of the evaluated products\n* Allergic reaction to the active ingredients of the evaluated products\n* Pregnancy and breastfeeding","18 Years",{"count":56,"type":22},200,[58],"PHASE2","The standard and most common therapy is anticoagulation with heparin according to activated partial thromboplastin time (aPTT) during extracorporeal membrane oxygenation (ECMO) support. The study will focus on evaluating the efficacy and safety of new anticoagulants on ECMO, namely argatroban and enoxaparin in lower doses controlled according to targeted antiIIa and antiXa markers.",[61,62],"Pneumonia","Heart Failure",[64,61,65,66],"ECMO","Heart failure","Anticoagulation","NOT_YET_RECRUITING","2026-03-27",{"date":70,"type":38},"2026-04-02",{"date":72,"type":22},"2027-01",{"date":74,"type":22},"2029-12",{"name":44,"class":45},2,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":76},"100627290","hyperbaric-oxygen-therapy-in-complex-regional-pain-syndrome-100627290","NCT07446712","Hyperbaric Oxygen Therapy in Complex Regional Pain Syndrome","Hyperbaric Oxygen Therapy in Complex Regional Pain Syndrome: a Randomised Controlled Trial","Inclusion Criteria:\n\n\\- Diagnosis of CRPS Type I (without nerve injury)\n\nExclusion Criteria:\n\n* HBOT contraindications (pregnancy; use of bleomycin, cisplatin, disulfiram, and doxorubicin; middle ear surgery; untreated pneumothorax or pneumomediastinum; ongoing acute infection; severe decompensation of organ functions or organ failure, severe claustrophobia)\n* Inability to sign the consent form",{"count":85,"type":22},60,[25],"The aim of the study is to investigate the efficacy of hyperbaric oxygen therapy as an adjunct in the management of severe complex regional pain syndrome.",[89,90],"Chronic Pain","Complex Regional Pain Syndrome",[90,89,92],"Hyperbaric Oxygen Therapy","2026-02-25",{"date":95,"type":38},"2026-03-03",{"date":97,"type":22},"2026-04",{"date":99,"type":22},"2029-04",{"name":44,"class":45},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":126,"locationsCount":76},"100606563","low-serum-creatinine-as-a-predictor-of-prolonged-mechanical-ventilation-and-weaning-failure-100606563","NCT07177183","Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure","SECRET-VENT","Inclusion Criteria:\n\n* Patients \\\u003C18 years of age\n* Patients admitted to post-ICU care units at Chronicare Group a.s. in the Czech Republic within 12 months\n\nExclusion Criteria:\n\n* Patients who are unlikely to be weaned from ventilatory support.\n* Patients in palliative care or with a survival probability of \\\u003C3 months\n* Patients with advanced malignancy\n* Patients with a history of chronic kidney disease\n* Patients with a history of chronic liver disease\n* Patients with supranormal serum creatinine on admission to the post-ICU care unit\n* Patients who refused to sign the Informed Consent with participation in the study.",{"count":109,"type":22},492,[25],"The main objective of the study is to determine whether a subnormal serum creatinine value upon admission to the Post-ICU Care Unit predicts the need for prolonged ventilatory support. A parallel objective of the study is to determine whether exogenous in-take of the dietary supplement creatine in patients with subnormal serum creatinine value is associated with a shortened duration of ventilatory support and improved patients outcome.",[113,114],"Prolonged Mechanical Ventilation","Critical Illness",[116,117,118,119],"Prolonged mechanical ventilation","Critical illness","Creatinine","Creatine supplementation","2026-02-02",{"date":122,"type":38},"2026-02-05",{"date":120,"type":22},{"date":125,"type":22},"2028-02-02",{"name":44,"class":45},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":151,"leadSponsor":153,"locationsCount":76},"100621720","on-scene-ecpr-in-ostrava-100621720","NCT07374289","On Scene ECPR in Ostrava","The Effectiveness of ECPR on the Scene and in Hospital for Out-of-hospital Cardi-ac Arrest (OHCA) in the Moravian-Silesian Region.","Inclusion Criteria:\n\n* Presumed cardiac aetiology of the cardiac arrest\n* Witnessed collapse\n* Bystander CPR\n* Estimated age ≤ 70 years\n* Body weight ≥15 Kg\n\nExclusion Criteria:\n\n* Known terminal malignant disease\n* Known terminal chronic disease","70 Years",{"count":136,"type":22},90,[25],"On-scene extracorporeal pulmonary resuscitation (ECPR) for out-of-hospital cardiac arrest (OHCA) seems to speed up the start of extracorporeal membrane oxygenation (ECMO) and shorten low flow during cardiopulmonary resuscitation (CPR) in case of refractory cardiac arrest. The primary goal is to verify the benefit of on-scene ECPR in terms of shortening the collapse-to-ECMO interval. The secondary goal is to compare outcomes in the on-scene ECPR group with hospital cannulation.",[140,141],"Cardiac Arrest (CA)","Cardiogenic Shock",[143,144,145,146],"extracorporeal membrane oxygenation","out-of-hospital cardiac arrest","cardiac arrest","cardiogenic shock","2026-01-28",{"date":149,"type":38},"2026-01-30",{"date":149,"type":22},{"date":152,"type":22},"2029-12-31",{"name":44,"class":45},{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":163,"briefSummary":164,"conditions":165,"keywords":170,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":182,"locationsCount":46},"100621009","comprehensive-analysis-of-the-swallowing-mechanism-using-high-resolution-manometry-with-impedance-100621009","NCT07365046","Comprehensive Analysis of the Swallowing Mechanism Using High-resolution Manometry With Impedance","Inclusion Criteria:\n\n* age 18-75 years\n* patients with swallowing difficulties suspected of having a functional oesophageal disorder or patients with clinical signs of extra-oesophageal reflux (Reflux Symptom Index \\[RSI\\] ≥ 13 or Reflux Symptom Score-12 \\[RSS-12\\] ≥ 11) signed informed consent\n\nExclusion Criteria:\n\n* patients with a diagnosed tumor of the esophagus or upper airway, or with strong clinical suspicion of a tumor of the esophagus or upper airway\n* severe neurological disease affecting swallowing\n* pregnancy\n* surgery involving the head, neck, or esophagus within the last 6 months","75 Years",{"count":162,"type":22},160,[25],"The aim of this project is to perform a detailed evaluation of upper esophageal sphincter function and the swallowing mechanism in patients with swallowing disorders or suspected extraesophageal reflux using high-resolution manometry with impedance and 24-hour pH-impedance monitoring.",[166,167,168,169],"Extraesophageal Reflux","Laryngopharyngeal Reflux","Dysphagia","Chronic Cough",[171,172,168,173,174,175],"Extraesophageal reflux","Laryngopharyngeal reflux","Chronic cough","high-resolution manometry","24-hour pH-impedance monitoring","2026-01-15",{"date":178,"type":38},"2026-01-23",{"date":180,"type":22},"2026-01",{"date":42,"type":22},{"name":44,"class":45},{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":134,"enrollmentInfo":191,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":76},"100596102","prehospital-ecpr-in-moravia-silesia-region-100596102","NCT07041086","Prehospital ECPR in Moravia Silesia Region","Prehospital ECPR in Moravia Silesia Region - Assessing the Effectiveness, Feasibility and Time of ECPR by Simulating Connections and Real Interventions.","01-Pain","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Observed collapse and presumption of cardiac cause of cardiac arrest\n* Estimated age up to 70 years\n* Baseline rhythm of ventricular fibrillation or pulseless electrical activity (PEA)\n* Basic bystander cardiopulmonary resuscitation (CPR), \"bystander CPR\", telephone assisted CPR (TANR)\n\nExclusion Criteria:\n\n* Children or adults with estimated weight below 40 kg\n* Known major comorbidities of the patient suggesting low rehabilitation potential (e.g. chronic obstructive pulmonary disease (COPD) IV, malignancy in tertiary phase)",{"count":192,"type":22},100,"OBSERVATIONAL","Cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest (OHCA) in specific cases could be improved by Extracorporeal membrane oxygenation (ECMO; ECPR). ECPR could be introduced in hospital after retrieval of an OHCA patient and also faster by implantation on scene. The aim is to verify the effectiveness of ECPR on scene in the Moravian-Silesian region.",[196],"Cardiac Arrest, Out-Of-Hospital",[64,198,199],"Cardiac arrest","Cardiopulmonary resuscitation","2026-01-13",{"date":176,"type":38},{"date":203,"type":38},"2025-06-17",{"date":205,"type":22},"2028-12-31",{"name":44,"class":45},{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":46},"100587393","utilization-of-virtual-reality-to-increase-comfort-and-reduce-procedural-distress-during-port-insertion-into-the-body-100587393","NCT06927804","Utilization of Virtual Reality to Increase Comfort and Reduce Procedural Distress During Port Insertion Into the Body","Utilization of Virtual Reality to Support Patient Comfort and Reduce Stress During the Implantation of a Subcutaneous Venous Port Prior to the Initiation of Oncological Treatment","Inclusion Criteria:\n\n* Patients \\> 18 years of age\n* Signed Informed Consent Form\n* Patients Indicated for oncology treatment administration using subcutaneous port\n\nExclusion Criteria:\n\n* Not signing of the Informed Consent Form\n* Patients \\\u003C 18 years of age\n* Patients unsuitable for subcutaneous port implantation",{"count":85,"type":22},[25],"This randomised controlled study evaluates whether virtual reality (VR) can support patient comfort and help reduce anxiety and stress during subcutaneous venous port implantation in adult oncology patients. Patients will be assigned to standard care or standard care with VR intervention.\n\nSubjective and objective measures of stress and discomfort will be collected, including the Visual Analog Scale (VAS) for self-reported procedural discomfort, physiological parameters (blood pressure, heart rate, variability), the STAI-6 questionnaire, and salivary cortisol.\n\nThe study aims to explore the potential of VR as a non-pharmacological, immersive tool to improve procedural experience and reduce psychological distress in patients undergo-ing minor oncological procedures.",[218],"Oncology Patients",[220,221,222,223,224],"Virtual reality","subcutaneous venous port","anxiety","stress","pain","2025-12-12",{"date":227,"type":38},"2025-12-19",{"date":229,"type":38},"2025-07-01",{"date":231,"type":22},"2026-12-31",{"name":44,"class":45},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":241,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":262},"100615963","effect-of-the-combination-of-dexamethasone-and-bis-monitoring-on-reducing-postoperative-nausea-and-vomiting-in-children-100615963","NCT07299435","Effect of the Combination of Dexamethasone and BIS Monitoring on Reducing Postoperative Nausea and Vomiting in Children","Effect of the Combination of Dexamethasone and BIS Monitoring on Reducing Postoperative Nausea and Vomiting in Children: a Multicenter Prospective Double-blind Study (BISDEX TRIAL)","BISDEX","Inclusion Criteria:\n\n* children aged 2 to 8 years undergoing endoscopic adenoidectomy\n* parental\u002Fchild consent\n* ASA I-II (American Society of Anaesthesiologists Physical Status)\n* no central nervous system (CNS) or gastrointestinal tract (GIT) disease\n* no corticosteroid medication\n\nExclusion Criteria:\n\n* Parent\u002Fchild disapproval\n* ASA III and above (American Society of Anaesthesiologists Physical Status)\n* central nervous system (CNS) or gastrointestinal tract (GIT) disease\n* chronic corticosteroid therapy","2 Years","8 Years",{"count":244,"type":22},1508,[25],"This study will investigate the impact of combining dexamethasone and bispectral index (BIS) monitoring on the incidence of postoperative nausea and vomiting, emergence delirium and recovery trajectories in children undergoing ear-nose-throat (ENT) surgery.",[248],"Tonsil Hypertrophy",[250,251,252,253],"postoperative nausea and vomiting","emergence delirium","children","ENT surgery","2025-12-09",{"date":256,"type":38},"2025-12-23",{"date":258,"type":22},"2026-01-05",{"date":260,"type":22},"2029-01",{"name":44,"class":45},5,{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":12,"sex":270,"minAge":54,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":273,"briefSummary":274,"conditions":275,"keywords":279,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":290,"locationsCount":46},"100609270","sacral-neuromodulation-in-patients-with-double-incontinence-100609270","NCT07212387","Sacral Neuromodulation in Patients With Double Incontinence","Effectiveness of Sacral Neuromodulation in Patients With Coexisting Faecal and Urinary Incontinence (\"Double Incontinence\")","Inclusion Criteria:\n\n* Adult women over 18 years of age\n* Consent to participate in the study\n* Willingness to undergo examination, treatment and follow-up according to the protocol\n* DI symptoms characterized by:\n* Grade III fecal incontinence (patient is unable to consciously hold in wind, loose or hard stools)\n* At least 2 episodes of fecal incontinence during the week (according to bladder and bowel diary)\n* At least 1 episode of involuntary urine leakage per day (according to bladder and bowel diary)\n* Total score of the ICIQ-UI SF questionnaire\n* DI symptoms for more than 6 months\n* Failure of previous conservative treatment\n\nExclusion Criteria:\n\n* Rapidly progressing neurological diseases\n* Known severe congenital malformations of the anorectum and\u002For lower urinary tract\n* Presence of a foreign body in the urinary tract - urolithiasis, urinary catheter, ureteral stent\n* Pregnancy, lactation\n* Active urinary tract infection\n* Active malignant disease\n* Clinically significant pelvic organ prolapse\n* Active inflammatory bowel disease (Crohn's disease, ulcerative colitis)\n* In the case of an associated lesion of the external anal sphincter, a defect greater than 90 degrees\n* Previous pelvic radiotherapy less than 12 months prior to study enrolment\n* Previous pelvic organ descent surgery less than 12 months prior to study enrolment\n* Previous stress urinary incontinence surgery less than 12 months prior to study enrolment\n* Previous childbirth less than 12 months prior to study enrollment\n* Anatomical malformations of the sacrum that preclude implantation of the SNM electrode\n* Low patient compliance\n* Inability to control the neurostimulator","FEMALE",{"count":272,"type":22},30,[25],"This is a prospective study evaluating the effect of a treatment method of sacral neuromodulation (SNM), the use of which is approved and recommended for the treatment of both faecal incontinence (FI) and urinary incontinence (UI). A new aspect of the study is monitoring the effect of SNM in patients with both types of incontinence (faecal and urinary) occurring simultaneously. The study will use diagnostic methods and procedures that are part of the usual examination algorithm. The study will not impose any burden on patients beyond the scope of routine examination and treatment procedures.",[276,277,278],"Double Incontinence","Faecal Incontinence","Urinary Incontinence",[280,281,282,283],"Double incontinence","Faecal incontinence","Urinary incontinence","Sacral neurostimulation","2025-09-30",{"date":286,"type":38},"2025-10-08",{"date":288,"type":22},"2025-11",{"date":74,"type":22},{"name":44,"class":45},{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":23,"phases":300,"briefSummary":301,"conditions":302,"keywords":304,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":319},"100607904","rectal-cancer-ctc-trial-100607904","NCT07194616","Rectal Cancer CTC Trial","Impact of Neoadjuvant Chemoradiotherapy Versus Surgery Alone on Circulating Tumor Cells in Patients With Stage II-III Rectal Cancer and Negative Circumferential Resection Margin: a Multicenter Randomized Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed rectal adenocarcinoma within 12 cm from anal verge\n* Stage II (cT3-4 N0 M0) or stage III (cT1-4 N1-2, M0)\n* Negative circumferential resection margin on staging MRI\n* ASA physical status I-III\n* Signed informed consent\n\nExclusion Criteria:\n\n* Tumor infiltration beyond fascia recti propria on MRI\n* Metastatic disease (stage IV)\n* Recurrent rectal cancer\n* Other concurrent malignancies\n* Emergency surgery required\n* Contraindication to surgery under general anesthesia",{"count":299,"type":22},120,[25],"This prospective, multi-centre, randomised clinical trial aims to compare the effect of neoadjuvant chemoradiotherapy versus primary surgery on circulating tumor cells (CTCs) in patients with stage II-III rectal cancer without circumferential resection mar-gin involvement. CTCs are considered a promising biomarker for disease dissemination and treatment response. Patients will be randomized to either primary surgical resection with total mesorectal excision or long-course neoadjuvant chemoradiotherapy followed by surgery. Serial blood samples will be collected at predefined time points to assess the presence and dynamics of CTCs. Secondary endpoints include perioperative morbidity and mortality, local recurrence rate, disease-free survival, and overall survival. The results of this study may provide new insights into the prognostic role of CTCs and contribute to optimising treatment strategies for rectal cancer.",[303],"Rectal Cancer Patients",[305,306,307,308,309,310],"circulating tumor cells","liquid biopsy","neoadjuvant chemoradiotherapy","prognostic biomarkers","rectal cancer","surgical resection","2025-09-18",{"date":313,"type":38},"2025-09-26",{"date":315,"type":38},"2025-04-01",{"date":317,"type":22},"2028-03-30",{"name":44,"class":45},4,{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":17,"minAge":326,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":76},"100551135","invasive-candidiasis-in-critical-care-100551135","NCT06456151","Invasive Candidiasis in Critical Care","Inclusion Criteria:\n\n* critically ill patients\n* new onset sepsis\n* rise in body temperature \\>38°C according to The Third Consensus Definitions for Sepsis and Septic Shock\n* colonization with Candida spp. from more than 1 non-sterile site\n* body temperature \\>38 °C despite 5 days of broad-spectrum antibiotic therapy with the presence of at least 1 of the following risk factors: abdominal surgery, secondary peritonitis, pancreatitis, central venous catheter (CVC) insertion, total parenteral nutrition (CPV), dialysis, steroid therapy, immunosuppressive therapy, or liver transplantation\n* microbiological test results will be reviewed and categorized based on whether Candida sp. is isolated from at least 2 non-sterile sites (±3 days) and whether there is an alternative microbiological diagnosis.\n\nExclusion Criteria:\n\n* not signing the informed consent with participation in the study\n* administration of antifungal therapy prior to collection of the biological material required for the study","12 Months",{"count":192,"type":22},"The combination of acute phase marker monitoring and the \"T2Candida\" assay (name of the test) will represent an acceleration of the identification of the causative agent of mycotic infection, a significant improvement in the specificity and positive predictive value of this strategy in the diagnosis of invasive candidiasis and candidemia in ICU patients, thereby improving the clinical condition of patients and reducing the cost of specific antifungal therapy.",[330],"Invasive Candidiasis",[332,333,334],"invasive candidiasis","biomarkers","candida sepsis","2025-06-02",{"date":337,"type":38},"2025-06-05",{"date":339,"type":38},"2024-04-11",{"date":341,"type":22},"2027-12",{"name":44,"class":45},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":17,"minAge":350,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":353,"conditions":354,"keywords":357,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":76},"100593685","optimization-of-transport-and-use-of-a-mobile-ecmo-team-in-patients-with-sudden-cardiac-arrest-in-the-moravian-silesian-region-100593685","NCT07009652","Optimization of Transport and Use of a Mobile ECMO Team in Patients With Sudden Cardiac Arrest in the Moravian-Silesian Region","Proposal for the Organisation of the Procedure for Extracorporeal Cardiopulmonary Resuscitation of Patients With Sudden Cardiac Arrest in the Pre-hospital Environment of the Moravian-Silesian Region","Inclusion Criteria:\n\n* out-of-hospital cardiac arrest\n* indication for ECPR\n\nExclusion Criteria:\n\n* death at the scene of the accident\n* withdrawal of the informed consent","3 Years","60 Years",{"count":192,"type":22},"This study evaluates the feasibility of implementing a mobile extracorporeal membrane oxygenation (ECMO) team and optimizing patient transport logistics.",[355,356],"Cardiac Arrest With Successful Resuscitation","Cardiac Arrest, Cause Unspecified",[145,143,144,358],"extracorporeal cardiopulmonary resuscitation","2025-05-29",{"date":361,"type":38},"2025-06-06",{"date":363,"type":38},"2025-05-01",{"date":365,"type":22},"2028-05-01",{"name":44,"class":45},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":375,"conditions":376,"keywords":378,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":46},"100534519","this-research-project-studies-the-relationship-between-osa-and-nocturia-100534519","NCT06239883","This Research Project Studies the Relationship Between OSA and Nocturia.","The Academic Research Project Studies the Relationship Between Obstructive Sleep Apnoea and the Occurrence of Nocturia.","Inclusion Criteria:\n\n* patients diagnosed obstructive sleep apnoea (OSA )\n* Apnea-Hypopnea Index (AHI) \\> 15\n* ability to fill in the voiding diaries\n* signed informed consent\n\nExclusion Criteria:\n\n* patients using diuretics\n* patients with malignancies\n* pregnancy",{"count":192,"type":22},"The main goal of the study is to explore the relationship between obstructive sleep apnoea and nocturia.",[377],"Obstructive Sleep Apnea",[377,379,380,381,382],"Nocturia","Lower urinary tract symptoms","Voiding diary","Nocturnal polyuria","2025-05-21",{"date":385,"type":38},"2025-05-28",{"date":387,"type":38},"2019-06-01",{"date":389,"type":22},"2026-12",{"name":44,"class":45},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":405,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":414,"leadSponsor":415,"locationsCount":319},"100587808","neoadjuvant-stereotactic-radiotherapy-for-brain-metastasis-100587808","NCT06933199","Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis","Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis - Prospective Trial NeoSTROBE","NeoSTROBE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Karnofsky Performance Status ≥ 60\n* Histologically verified primary cancer disease\n* MRI findings indicating BM\n* Target BM indicated for surgical resection and any other metastases suitable for radical SRT.\n* Target BM between 1 cm and 7 cm at the longest diameter on T1 post-contrast MR imaging\n\nExclusion Criteria:\n\n* Confirmed hematological malignity\n* Small-cell (lung) carcinoma\n* Peracute condition requiring immediate neurosurgical intervention\n* History of whole-brain radiotherapy (WBRT)\n* History of stereotactic radiotherapy to a target brain metastasis\n* Pregnancy\n* Inability to perform surgical resection of the target BM within 7 days after NaSRT",{"count":400,"type":22},260,[25],"This multicentre proof-of-concept study, involving 4 centers, aims to establish the value of fractionated neoadjuvant stereotactic radiotherapy (NaSRT) as a new treatment paradigm for brain metastases (BM) in the frame of the Czech neurooncology network. Most relevant studies published to date used single-fraction radiotherapy and dealt with the inherent bias related to their retrospective nature. The researchers aim to increase the level of evidence for this treatment paradigm together with other similar ongoing studies.",[404],"Brain Metastases",[404,406,407,408,409,410],"Neoadjuvant Stereotactic Radiotherapy","Leptomeningeal Disease","Quality of Life","Overall Survival","Acute Toxicity",{"date":412,"type":38},"2025-05-04",{"date":363,"type":22},{"date":205,"type":22},{"name":44,"class":45},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":270,"minAge":54,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":424,"conditions":425,"keywords":427,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":432,"leadSponsor":434,"locationsCount":319},"100586927","changes-in-the-urinary-microbiome-and-metabolome-during-treatment-of-the-overactive-bladder-in-female-patients-100586927","NCT06921746","Changes in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients","Inclusion Criteria:\n\n* Adult women over 18 years of age\n* Written consent to participate in the study\n* Willingness to undergo OAB evaluation and treatment according to the protocol\n* OAB symptoms lasting longer than 3 months\n* At least 3 episodes of severe urgency with or without urge incontinence within 3 days documented by voiding diary\n* OAB symptom score V8 questionnaire ≥ 8\n\nExclusion Criteria:\n\n* Known congenital developmental defects of the urinary tract (congenital hydronephrosis, vesicoureteral reflux, renal agenesis and hypoplasia, multicystic and polycystic kidneys)\n* Any previous treatment for OAB\n* Recurrent urinary tract infections (more than 3 episodes in the last 12 months)\n* Presence of a foreign body in the urinary tract - urolithiasis, urinary catheter, ureteral stent\n* Acute or chronic diseases with possible influence on the function of the lower urinary tract (LUT)\n* Rheumatoid arthritis\n* Diabetes mellitus",{"count":423,"type":22},80,"This is a non-interventional study that will not pose any burden for the participants. The study subjects will be examined and treated in a standard manner according to current clinical recommendations for the treatment of overactive bladder (OAB). A portion of urine samples, which are routinely collected for biochemical and culture examinations as part of the diagnostic process, will be sent for examination of the characteristics of the urinary microbiome and metabolome (UMM) before and after treatment.",[426],"Overactive Bladder",[426,428,429],"Urinary Microbiome","Urinary Metabolome",{"date":412,"type":38},{"date":363,"type":22},{"date":433,"type":22},"2027-12-31",{"name":44,"class":45},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":441,"minAge":54,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":23,"phases":443,"briefSummary":444,"conditions":445,"keywords":447,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":458,"locationsCount":46},"100567264","stereotactic-radiotherapy-of-prostate-cancer-with-reduction-of-safety-margins-100567264","NCT06665932","Stereotactic Radiotherapy of Prostate Cancer With Reduction of Safety Margins","Inclusion Criteria:\n\n* histologically verified, localized prostate cancer without regional lymphadenopathy or distant metastases\n* low or intermediate risk - favorable risk\n* staging according to NCCN recommendations:\n* low risk: no staging required\n* intermediate risk- favorable risk: CT abdomen and pelvis\n* PSA up to 15\n* age over 18 years\n* signed informed consent form\n* suitable position of fiducials (to be determined by the physicist)\n\nExclusion Criteria:\n\n* a histological type other than acinar adenocarcinoma\n* the presence of local lymphadenopathy or distant metastases\n* a dominant lesion in the periphery that is in contact with the capsule or grows through it\n* PSA over 15\n* unsatisfactory position of fiducials (to be determined by the physicist)\n* previous treatment with radiotherapy to the pelvic area","MALE",{"count":192,"type":22},[25],"The study aims to reduce the PTV (Planning Target Volume) safety margins to 1-2 mm in stereotactic prostate radiotherapy for low- and medium-risk prostate cancers while maintaining a dose of 36.25 Gy in 5 fractions per day. By reducing the hems, the investigators expect a reduction of acute and late toxicity on the organs at risk, dominantly the urethra, bladder, penile bulb, and rectum, and an improvement in the quality of life.",[446],"Prostate Cancer (Adenocarcinoma)",[448,449,450,451],"prostate cancer","Stereotactic Body Radiotherapy","acute toxicity","late toxicity","2024-11-07",{"date":454,"type":38},"2024-11-12",{"date":456,"type":22},"2024-11-01",{"date":433,"type":22},{"name":44,"class":45},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":465,"sex":270,"minAge":466,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":468,"conditions":469,"keywords":471,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":482,"locationsCount":46},"100560183","the-urinary-microbiome-and-its-relationship-to-the-urinary-and-serum-metabolome-in-healthy-peri--and-postmenopausal-women-100560183","NCT06573827","The Urinary Microbiome and Its Relationship to the Urinary and Serum Metabolome in Healthy Peri- and Postmenopausal Women","Inclusion Criteria:\n\n* Women over 50 years old\n* Consent to participate in the study\n* Willingness to take urine and blood samples according to the protocol\n\nExclusion Criteria:\n\n* Known congenital developmental defects of the urinary tract (congenital hydronephrosis, vesicoureteral reflux, renal agenesis, and hypoplasia, multicystic and polycystic kidneys)\n* Recurrent urinary tract infections (more than 3 episodes in the last 12 months)\n* Presence of any lower-urinary tract symptoms (urgency, frequency, incontinence, stranguria, urge to urinate, weak urine stream, the feeling of post-micturition residue)\n* The presence of a foreign body in the urinary tract - urolithiasis, urinary catheter, ureteral stent\n* Acute or chronic diseases with possible influence on lower-urinary tract function\n* Medications with possible influence on lower-urinary tract function\n* Rheumatoid arthritis\n* Diabetes mellitus",true,"50 Years",{"count":192,"type":22},"The presented project aims to characterize the microbiome of healthy peri- and postmenopausal women and its correlation with the metabolome of urine and serum.",[470],"Urinary Tract Infections",[472,473,474,475],"microbiome","urinary metabolome","urinary bladder","menopause","2024-08-23",{"date":478,"type":38},"2024-08-27",{"date":480,"type":22},"2024-09-01",{"date":205,"type":22},{"name":44,"class":45},{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":489,"targetDuration":4,"studyType":23,"phases":491,"briefSummary":492,"conditions":493,"keywords":495,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":46},"100551234","molecular-characteristics-and-prevalence-of-viral-hepatitis-e-in-human-tissue-and-cell-donors-100551234","NCT06457438","Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors","Inclusion Criteria:\n\n\\- patients indicated for organ or cell donation\n\nExclusion Criteria:\n\n\\- none",{"count":490,"type":22},300,[25],"In this study, the researchers want to focus on the prevalence of anti-HEV antibodies by a new generation test, direct detection of HEV RNA, and its genotypic analysis in a group of human tissue and cell donors.",[494],"Hepatitis E",[494,496,497,498],"Organ Donor","Cell Donor","HEV RNA","2024-06-07",{"date":501,"type":38},"2024-06-13",{"date":503,"type":38},"2022-01-01",{"date":505,"type":22},"2024-12",{"name":44,"class":45},{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":441,"minAge":54,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":516,"conditions":517,"keywords":518,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":529,"locationsCount":46},"100534521","adjustable-artificial-sphincter-victo-in-the-treatment-of-male-incontinence-due-to-prostate-surgery-100534521","NCT06239909","Adjustable Artificial Sphincter Victo in the Treatment of Male Incontinence Due to Prostate Surgery","Clinical Outcomes of the Adjustable Artificial Sphincter Victo in the Treatment of Male Incontinence Due to Prostate Surgery - Prospective Follow-up Study","Inclusion Criteria:\n\n* urinary incontinence due to previous prostate surgery\n* primo-implantation of the artificial urinary sphincter\n* subject willing and able to give informed consent\n\nExclusion Criteria:\n\n\\- none",{"count":515,"type":22},150,"The aim of this prospective academic research study is to evaluate the efficacy and safety of the Victo adjustable artificial sphincter in the treatment of male patients with urinary incontinence due to prostate surgery.",[278],[519,520,521,522],"urinary incontinence","artificial urinary sphincter","pad-weight test","quality of life","2024-01-25",{"date":525,"type":38},"2024-02-02",{"date":527,"type":38},"2018-05-01",{"date":389,"type":22},{"name":44,"class":45},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":538,"enrollmentInfo":539,"targetDuration":4,"studyType":23,"phases":541,"briefSummary":542,"conditions":543,"keywords":545,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":556,"locationsCount":46},"100469298","carotid-endarterectomy-vs-repeated-carotid-angioplasty-and-stenting-for-in-stent-restenosis-100469298","NCT05390983","Carotid Endarterectomy vs. Repeated Carotid Angioplasty and Stenting for In-Stent Restenosis","Comparison of Carotid Endarterectomy and Repeated Carotid Percutaneous Transluminal Angioplasty With or Without Stenting for In-stent Restenosis","CERCAS","Inclusion Criteria:\n\n* In-stent restenosis in carotid artery 70 - 99 %\n* Indication to carotid intervention\n* Age 18-80 years\n* Functionally independent with a modified Rankin score value of 0 - 2 points\n* Signed Informed consent\n\nExclusion Criteria:\n\n* Contraindication to general anesthesia\n* Contraindication to angiography (iodine allergy, etc.)\n* Technically impossible to perform angioplasty with or without stenting\n* Participation in other clinical study within 60 days\n* Technically impossible to perform carotid endarterectomy","80 Years",{"count":540,"type":22},40,[25],"Patients with in-stent restenosis in carotid artery indicated to carotid intervention will be randomized into repeated carotid percutaneous transluminal angioplasty with or without stenting or carotid endarterectomy with stent removal. The objective of the randomized study is to compare the safety and effectiveness of CEA and CAS in patients with in-stent restenosis of the ICA.",[544],"In-Stent Carotid Artery Restenosis",[546,547,548,549],"endarterectomy","percutaneous transluminal angioplasty","stenting","in-stent restenosis","2024-01-17",{"date":552,"type":38},"2024-01-18",{"date":554,"type":38},"2017-05-25",{"date":341,"type":22},{"name":44,"class":45},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":565,"conditions":566,"keywords":569,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":578,"locationsCount":46},"100532908","the-effect-of-autologous-hematopoietic-stem-cell-transplantation-on-the-lower-urinary-tract-function-related-to-qol-in-ms-patients-100532908","NCT06218927","The Effect of Autologous Hematopoietic Stem Cell Transplantation on the Lower Urinary Tract Function Related to QoL in MS Patients","The Effect of Autologous Hematopoietic Stem Cell Transplantation on the Lower Urinary Tract Function Related Quality of Life in Multiple Sclerosis Patients","Inclusion Criteria:\n\n* Subjects (male and female) aged 18 and over\n* Subjects with signed informed consent\n* Subjects able to undergo examination according to the protocol\n* Patients indicated by neurologists to perform AHSCT or treated with the closest similar disease-modifying therapy (control group)\n\nExclusion Criteria:\n\n* Subjects with a history of bladder cancer\n* Subjects after previous pelvic radiotherapy\n* Subjects with evidence of microscopic or macroscopic hematuria\n* Subjects with a history of bladder reconstruction (augmentation cystoplasty, catheterizable stoma), subjects after cystectomy\n* Treatment with botulinum toxin injection into the bladder wall in the last 12 months\n* Patients in whom the pharmacological treatment of the lower urinary tract has not been stable in the last 3 months and is being adjusted\n* Patients whose lower urinary tract symptoms are not stable for at least 3 months\n* Patients with a permanent catheter\n* Patients with recurrent symptomatic lower urinary tract infections - 3 or more episodes of infection in the last 12 months\n* Subjects with tubal urine screening-proven bacteriuria\n* Patients with acute lower urinary tract inflammation at baseline\n* Subjects with painful bladder syndrome\n* Patients after sacral neuromodulation\n* Patients with severe pelvic organ prolapse\n* Patients after radical pelvic surgery\n* Patients with a life expectancy of less than 5 years at the time of inclusion in the study\n* Lactating women, pregnant women, women trying to get pregnant, or sexually active women without a tendency to use safe contraception (hormonal-based oral contraceptives, injectable contraception, hormonally active implants, sexual abstinence, vasectomy in a partner)\n* Subjects who participated in another study in the previous 90 days",{"count":540,"type":22},"Academic research project monitoring the effect of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) on multiple sclerosis-associated lower urinary tract symptoms.",[567,568],"Multiple Sclerosis","Lower Urinary Tract Symptoms",[567,568,570,571,408],"Autologous Hematopoietic Stem Cell Transplantation","Disease-Modifying Therapy","2024-01-12",{"date":574,"type":38},"2024-01-23",{"date":576,"type":38},"2023-11-01",{"date":389,"type":22},{"name":44,"class":45},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":4,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":588,"conditions":589,"keywords":591,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":606,"locationsCount":607},"100519584","multimodal-ct-examination-in-stroke-mimics-diagnosis-100519584","NCT06045455","Multimodal CT Examination in Stroke Mimics Diagnosis","The Importance of Multimodal CT Examination in Stroke Mimics Diagnosis: a Prospective Observational Multicenter Study","Inclusion Criteria:\n\n\\- an acute focal neurological deficit (minimum 1 point on the National Institutes of Health Stroke Scale - NIHSS) within 24 hours from the onset of symptoms\n\nExclusion Criteria:\n\n* the last period of normality is unknown prior to multimodal CT examination\n* the last period of normality is \\>24 hours prior to multimodal CT examination\n* the diagnostic evaluation is incomplete\n* a final neurologic diagnosis cannot be determined",{"count":587,"type":22},3000,"The proposed project is a multicentre prospective observational clinical research focused on refining multimodal computer tomography (CT) diagnostics in stroke mimics. The main aim is to accurately identify SM in order to minimize the risk of receiving inappropriate treatment and possible development of complications, which can have a negative impact on the patient´s health. The project includes an analysis of pharmacoeconomic parameters. It will examine saved costs in the case of non-administration of unindicated treatment and it will compare the number of adverse events related to the administration of unindicated treatment in patients diagnosed with SM.",[590],"Stroke Mimics",[592,593,594,595,596,597,598,599,600],"stroke mimics","neurological disorders","cerebrovascular accident","brain disorders","computer tomography","CT angiography","non-contrast head computed tomography","intravenous thrombolysis","National Institutes of Health Stroke Scale",{"date":602,"type":38},"2024-01-16",{"date":604,"type":38},"2023-10-01",{"date":389,"type":22},{"name":44,"class":45},3,{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":612,"acronym":4,"eligibilityCriteria":613,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":614,"targetDuration":4,"studyType":193,"phases":4,"briefSummary":615,"conditions":616,"keywords":619,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":632,"locationsCount":633},"100505363","early-diagnosis-of-invasive-lung-aspergillosis-100505363","NCT05860387","Early Diagnosis of Invasive Lung Aspergillosis","Inclusion Criteria:\n\n* respiratory rate ≥ 30 breaths\u002Fmin\n* PaO2\u002FFiO2 ratio ≤ 250\n* multilobar infiltrates\n* confusion\u002Fdisorientation\n* uremia (blood urea nitrogen level ≥ 20mg\u002FdL)\n* leucocytosis (white blood cell count \\> 12000\u002FmL) or\n* leukopenia (white blood cell count \\\u003C 4 x 109\u002FL)\n* thrombocytopenia (platelet count \\\u003C 100 x 109\u002FL)\n* hyperthermia (core temperature \\> 38 °C)\n* hypothermia (core temperature \\\u003C 36 °C)\n* hypotension requiring aggressive fluid resuscitation\n* invasive mechanical ventilation and septic shock requiring vasopressors\n* Bronchoalveolar Lavage Fluid (BALF) and\u002For Endotracheal Aspirate (ETA)\n\nExclusion Criteria:\n\n\\- patients, in whom PTX3, Aspergillus qPCR, and HPLC-FTICR were not performed or were performed after the start of antifungal treatment",{"count":515,"type":22},"The last decade has seen a significant increase in secondary Aspergillus infections, not only due to primary hypersensitivity, and immunodeficiency based on oncological diseases and their therapy, but mainly due to a rise in severe respiratory infections (H1N1, COVID-19, bacterial infections). This is most evident in critically ill patients whose life is threatened by invasive pulmonary aspergillosis (IPA), with over 90 % of cases being caused by Aspergillus fumigatus. In recent decades, various biomarkers with well-known limits of use (Aspergillus DNA, galactomannan, 1,3-ß-D-glucan) have been used for early diagnosis of IPA. However, the clinical need to clearly distinguish the onset of IPA from colonization is much more significant. The current biomarkers only provide \"probable IPA\" interpretation, and the diagnosis is rarely confirmed. Based on our preliminary studies, the use of new low molecular weight substances (secondary metabolites) combined with acute-phase proteins (pentraxin 3) allows very reliable immediate confirmation of IPA. In tissue samples, bronchoalveolar lavage fluid, endotracheal aspirate, breath condensate, serum, and urine of critically ill patients, the investigators will be able to recognize and confirm IPA in time using highly sensitive mass spectrometry detecting specific microbial siderophores in correlation with a significantly increased concentration of acute-phase host protein (pentraxin 3) within hours of the beginning of the invasion of lung tissue. Through a prospective multicentre study, the investigators will evaluate the benefit of new biomarkers in non-invasive IPA confirmation, improve the IPA diagnostic algorithm and transfer the detection method to MALDI-TOF spectrometers widely used in Clinical laboratories in the Czech Republic. In MALDI-TOF mass spectrometry, the ion source is matrix-assisted laser desorption\u002Fionization (MALDI), and the mass analyser is a time-of-flight (TOF) analyser.\n\nThe study results will contribute to a high clarity of IPA cases, the accurate introduction of antifungal therapy, and a better prognosis of survival of critically ill patients.",[617,618],"Respiratory Infection","Invasive Pulmonary Aspergillosis",[333,620,621,622,623,624,625],"qualitative polymerase chain reaction (qPCR)","metallomics","mass spectrometry","colonisation","invasive pulmonary aspergillosis","Pentraxin-3","2023-09-06",{"date":628,"type":38},"2023-09-07",{"date":630,"type":38},"2023-05-31",{"date":231,"type":22},{"name":44,"class":45},7,{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":4,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":641,"targetDuration":4,"studyType":23,"phases":642,"briefSummary":643,"conditions":644,"keywords":646,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":651,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":46},"100500300","the-safe-prospective-registry-100500300","NCT05794464","The SAFE Prospective Registry","Secretoneurin as a Biomarker of Atrial Fibrillation rEcurrence After Catheter Ablation\u002FElectrical Cardioversion","Inclusion Criteria:\n\n* Atrial fibrillation (Afib); (paroxysmal, persistent)\n* Patients indicated for catheter ablation and\u002For electrical cardioversion\n* Signed informed consent\n\nExclusion Criteria:\n\n* Longstanding or permanent atrial fibrillation\n* Severe mitral regurgitation\n* Heart failure with a permanently reduced ejection fraction\n* Cerebral ischaemic stroke in \\\u003C 3 months\n* Severe kidney injury\n* Severe renal insufficiency\n* Hepatic insufficiency limiting biomarker sampling\n* Myocardial infarction \\\u003C 3 months",{"count":85,"type":22},[25],"Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.",[645],"Atrial Fibrillation, Paroxysmal or Persistent",[647,648,649,650],"atrial fibrillation","secretoneurin","catheter ablation","electrical cardio version",{"date":628,"type":38},{"date":653,"type":38},"2023-05-01",{"date":655,"type":22},"2026-08",{"name":44,"class":45},""]